autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT01815749)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Burkitt Lymphoma · Phase 1
- Hodgkin Disease · Phase 1
- Intraocular Lymphoma · Phase 1
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Prolymphocytic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Testicular Neoplasms · Phase 1
- Transplantation · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02153580 | Phase 1 | Sep 1, 2014 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01815749 | Phase 1 | Sep 1, 2013 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1